8. Ayala G, Wang DG, Wulf G, Frolov A, Li R, Sowadski J, Wheeler TM, Lu KP, Bao L, The
prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer. Cancer Res.
2003;63:6244-6251.
9. Yu Q, Geng Y, Sicinski P, Specific protection against breast cancers by cyclin D1 ablation.
Nature. 2001;411:1017-1021.
10. Yaffe MB, Schutkowski M, Shen M, Zhou XZ, Stukenberg PT, Rahfeld JU, Xu J, Kuang J,
Kirschner MW, Fischer G, Cantley LC, Lu KP, Sequence-specific and
phosphorylation-dependent proline isomerization: A potential mitotic regulatory mechanism.
Science. 1997;278:1957-1960.
11. Hennig L, Christner C, Kipping M, Schelbert B, Rücknagel KP, Grabley S, Küllertz G,
Fischer G. Selective inactivation of parvulin-like peptidyl-prolyl cis/trans isomerases by
Juglone. Biochemistry. 1998;37:5953-5960.
12. Uchida T, Takamiya M, Takahashi M, Miyashita H, Ikeda H, Terada T, Matsuo Y, Shirouzu
M, Yokoyama S, Fujimori F, Hunter T. Pin1 and Par14 peptidyl prolyl isomerase inhibitors
block cell proliferation. Chemistry & Biology. 2003;10:15-24.
13. Potter AJ, Oldfield V, Nunns C, Fromont C, Ray S, Northfield CJ, Bryant CJ, Scrace SF,
Robinson D, Matossova N, Baker L, Dokurno P, Surgenor AE, Davis B, Richardson CM,
Murray JB, Moore JD. Discovery of cell-active phenyl-imidazole Pin1 inhibitors by
structure-guided fragment evolution. Bioorg. Med. Chem. Lett. 2010;20:6483-6488.
14. Potter AJ, Ray S, Gueritz L, Nunns CL, Bryant CJ, Scrace SF, Matassova N, Baker L,
Dokurno P, Robinson DA, Surgenor AE, Davis B, Murry JB, Richardson CM, Moore JD.
Structure-guided design of α-amino acid-derived Pin1 inhibitors. Bioorg. Med. Chem. Lett.
2010;20:586-590.
15. Guo C, Hou X, Dong L, Dagostino E, Greasley S, Ferre R, Marakovits J, Johnson MC,
Matthews D, Mroczkowski B, Parge H, VanArsdale T, Popoff I, Piraino J, Margosiak S,
Thomson J, Los G, Murry BW. Structure-based design of novel human Pin1 inhibitors (Ⅰ),
Bioorg. Med. Chem. Lett. 2009;19:5613-5616.
16. Dong L, Marakovits J, Hou X, Guo C, Greasley S, Dagostino E, Ferre R, Johnson MC,
Kraynov E, Thomson J, Pathak V, Murry BW. Strucure-based design of novel human Pin1
inhibitors (Ⅱ). Bioorg. Med.Chem. Lett. 2010;20:2210-2214.
17. Guo C, Hou X, Dong L, Marakovits J, Greasley S, Dagostino E, Ferre R, Johnson MC,
Humphries PS, Li H, Paderes GD, Piraino J, Kraynov E, Murry BW. Structure-based design
of novel human Pin1 inhibitors (Ⅲ): Optimizing affinity beyond the phosphate recognition
pocket. Bioorg. Med. Chem. Lett. 2014;24:4187-4191.
18. Wei S, Kozono S, Kats L, Nechama M, Li W, Guarnerio J, Luo M, You M, Yao Y, Kondo A,
Hu H, Bozkurt G, Moerke NJ, Cao S, Reschke M, Chen C, Rego EM, Lo-Coco F, Cantley
LC, Lee TH, Wu H, Zhang Y, Pandolfi PP, Zhou XZ, Lu KP. Active Pin1 is a key target of
all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. nature medicine.
2015;21:457-469.
19. Ranganathan R, Lu KP, Hunter T, Noel JP. Structural and functional analysis of the mitotic
rotamase Pin1 suggests substrate recognition is phosphorylation dependent. Cell.
1997;89:875-886.
20. Zhu L, Jin J, Liu C, Zhang C, Sun Y, Guo Y, Fu D, Chen X, Xu B, Synthesis and biological
evaluation of novel quinazoline-derived human Pin1 inhibitors. Bioorg. Med. Chem.